A Study of LY3478045 in Healthy Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-16

Study Completion Date

2021-06-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study in healthy participants is to learn more about the safety of LY3478045 and any side effects that might be associated with it. The study will also measure how much LY3478045 gets into the bloodstream and how long it takes the body to get rid of it.

This study has two parts: Part A (one dose) will last about six weeks and Part B (more than one dose) will last about eight weeks for each participant.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3502970 in Healthy Participants

NCT03929744

Healthy

COMPLETED PHASE1

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

NCT02714569

Dyslipidemias

COMPLETED PHASE1

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

NCT01105975

Dyslipidemia

COMPLETED PHASE2

A Study of LY3015014 in Healthy Participants With High Cholesterol

NCT01671085

Healthy Volunteers Hypercholesterolemia

COMPLETED PHASE1

A Study of LY2484595 in Japanese Subjects

NCT01375075

Dyslipidemias

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3478045 (Part A)

Participants received single ascending oral dose of 20 milligram (mg), 60mg, 180 mg, 500 mg, 700 mg LY3478045 on Day 1.

Group Type EXPERIMENTAL

LY3478045

Intervention Type DRUG

Administered orally.

Placebo (Part A)

Participants received single oral dose of placebo on Day 1.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally.

LY3478045 (Part B)

Participants received multiple ascending oral dose of 60mg and 300 mg LY3478045 once-daily (QD)for 14 days.

Group Type EXPERIMENTAL

LY3478045

Intervention Type DRUG

Administered orally.

Placebo (Part B)

Participants received oral dose of placebo QD for 14 days.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally.

LY3478045 + Atorvastatin (Part B)

Participants received multiple ascending oral doses of 160 mg, 360 mg LY3478045 QD for 14 days and 40 mg atorvastatin administered orally 4 hours after breakfast on Day -2 and 4 hours after LY3478045 administration on Day 7.

Group Type EXPERIMENTAL

LY3478045

Intervention Type DRUG

Administered orally.

Atorvastatin

Intervention Type DRUG

Administered orally.

Placebo + Atorvastatin (Part B)

Participants received oral dose of placebo QD for 14 days and 40 mg atorvastatin administered orally 4 hours after breakfast on Day -2 and 4 hours after LY3478045 administration on Day 7.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally.

Atorvastatin

Intervention Type DRUG

Administered orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3478045

Administered orally.

Intervention Type DRUG

Placebo

Administered orally.

Intervention Type DRUG

Atorvastatin

Administered orally.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are overtly healthy participants as determined through medical history and physical examination
* Have a body mass index greater than or equal to (≥)18.5 and less than or equal to (≤)40 kilograms per square meter (kg/m²)
* Have had a stable weight for 3 months prior to screening and enrollment (less than \[\<\]5 percent \[%\] body weight change) and have not received dietary intervention in the 3 months prior to screening and enrollment
* Have safety laboratory test results within the normal reference range for the population or investigative site, or results with acceptable deviations that are judged as not clinically significant by the investigator

Exclusion Criteria

* Have a history of fructosuria
* Have an abnormality in the 12-lead electrocardiogram (ECG) at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG (QT) data analysis
* Have blood pressure greater than (\>)160/90 millimeters of mercury (mmHg) and pulse rate \<50 or \>100 beats per minute (bpm), supine (at screening), or with minor deviations judged to be acceptable by the investigator
* Use of any drugs or substances that are known strong inducers or inhibitors of cytochrome P450 (CYP)3A or organic anion-transporting polypeptides (OATPs) are specifically excluded within 14 days prior to the first administration of study drug and during the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes